Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

CD8 + T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

Francesco Mazziotta, Luca Biavati, Joseph Rimando, Sergio Rutella, Nicholas Borcherding, Sonali Parbhoo, Rupkatha Mukhopadhyay, Sayan Chowdhury, Hanna A. Knaus, Peter Valent, Hubert Hackl, Ivan M. Borrello, Bruce R. Blazar, Katerina Hatzi, Ivana Gojo, Leo Luznik

Blood (2024) 144 (11): 1168–1182.

https://doi.org/10.1182/blood.2023021680

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Joseph Rimando, Francesco Mazziotta, Alison Gareau, Maria Bettinotti, Jonathan Allen Webster, Syed Abbas Ali, Philip Imus, Mario Victor Lemas, Amy E. DeZern, Mark J. Levis, Marianna Zahurak, Ravi Varadhan, Richard F. Ambinder, Carol Huff, Ivana Gojo, Richard J. Jones, Ivan M. Borrello, Leo Luznik

Blood (2023) 142 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2023-179394

Published: 2023

Journal Articles

Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Francesco Mazziotta, Luca Biavati, Sonali Parbhoo, Sayan Chowdhury, Joseph Rimando, Ivan M. Borrello, Katerina Hatzi, Bruce R. Blazar, Ivana Gojo, Leo Luznik

Blood (2022) 140 (Supplement 1): 9132–9133.

https://doi.org/10.1182/blood-2022-167107

Published: 2022

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Bone Marrow GZMK + IL7R + Progenitor-Exhausted CD8 + T Cells Correlate with Sustained Clinical Remission in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Francesco Mazziotta, Luca Biavati, Rupkatha Mukhopadhyay, Hanna A. Knaus, Ivan M. Borrello, Ivana Gojo, Leo Luznik

Blood (2021) 138 (Supplement 1): 521.

https://doi.org/10.1182/blood-2021-149150

Published: 2021

Journal Articles

High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study

Blood (2021) 138 (Supplement 1): 152.

https://doi.org/10.1182/blood-2021-149868

Published: 2021

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

Treating MRD Positivity in Multiple Myeloma: An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Long-Term Remissions in Patients with Low Disease Burden

Luca Biavati, MD, Carol Ann Huff, MD, Anna Ferguson, BSN, RN, Lakshmi Rudraraju, MS, Cristina Zucchinetti, Rachel Gittelman, Sarah Johnson, Catherine Sanders, Abbas Abbas Ali, MD, Kimberly Noonan, PhD MPH, Ivan M. Borrello, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-142620

Published: 2020

Journal Articles

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Luca Biavati, MD, Anna Ferguson, BSN, RN, Carol Ann Huff, MD, Lakshmi Rudraraju, MS, Rachel Gittelman, Sarah Johnson, Catherine Sanders, Syed Abbas Ali, MD, Kimberly Noonan, PhD MPH, Ivan M. Borrello, MD

Blood (2019) 134 (Supplement_1): 1895.

https://doi.org/10.1182/blood-2019-128430

Published: 2019

Journal Articles

Superior Efficacy of CAR-T Cells Using Marrow-Infiltrating Lymphocytes (MILs TM ) As Compared to Peripheral Blood Lymphocytes (PBLs)

Eric R. Lutz, PhD, Srikanta Jana, PhD, Lakshmi Rudraraju, MS, Elizabeth DeOliveira, Jing Zhou, Sean Mackay, Ivan M. Borrello, MD, Kimberly Noonan, PhD MPH

Blood (2019) 134 (Supplement_1): 4437.

https://doi.org/10.1182/blood-2019-130629

Published: 2019

Journal Articles

Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets

Blood (2019) 134 (Supplement_1): 4355.

https://doi.org/10.1182/blood-2019-122088

Published: 2019

Journal Articles

Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy

Eric R. Lutz, PhD, Valentina Hoyos, MD, Lakshmi Rudraraju, MS, Elizabeth DeOliveira, Srikanta Jana, PhD, Ido Weiss, PhD, Ivan M. Borrello, MD, Kimberly Noonan, PhD MPH

Blood (2018) 132 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2018-99-118580

Published: 2018

Journal Articles

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Blood (2017) 130 (Supplement 1): 2593.

https://doi.org/10.1182/blood.V130.Suppl_1.2593.2593

Published: 2017

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

Journal Articles

Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile

Meghali Goswami, Gabrielle T. Prince, MD, Angelique Biancotto, PhD, Susan Moir, PhD, Foo Cheung, PhD, Yuri Kotliarov, PhD, Kimberly Dunham, Jinguo Chen, MD, Rongye Shi, MD, Huizhi Zhou, Hana Golding, PhD, Jingrong Tang, MD PhD, John S. Tsang, PhD, Howard B. Dickler, MD, Kimberly Noonan, PhD MPH, B. Douglas Smith, MD, Ivan M. Borrello, MD, Christopher S. Hourigan, MD PhD

Blood (2015) 126 (23): 3427.

https://doi.org/10.1182/blood.V126.23.3427.3427

Published: 2015

Journal Articles

Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission

Ivan M. Borrello, MD, Kimberly Noonan, PhD MPH, Carol Ann Huff, Anna Ferguson, BSN, RN, Amy Sidorski, CRNP, Lakshmi Rudraraju, Raffaello Cimbro, MS, Luigi Marchionni, MD PhD

Blood (2015) 126 (23): 4238.

https://doi.org/10.1182/blood.V126.23.4238.4238

Published: 2015

Journal Articles

The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients

Samuel A. Funt, MD, David B. Page, MD, Deepika Cattry, BSc, MSc, Nikoletta Lendvai, MD PhD, Hani Hassoun, MD, Ola Landgren, MD PhD, Ivan M. Borrello, MD, Alexander M. Lesokhin, MD

Blood (2015) 126 (23): 3057.

https://doi.org/10.1182/blood.V126.23.3057.3057

Published: 2015

Journal Articles

Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)

Nilanjan Ghosh, MD, PhD, Xiaobu Ye, MD, MS, Javier Bolaños-Meade, MD, Ephraim J. Fuchs, Leo Luznik, Jennifer A. Kanakry, Robert A. Brodsky, MD, Mark Levis, MD, PhD, Lode J. Swinnen, Douglas Gladstone, MD, Yvette L. Kasamon, Richard F. Ambinder, Richard J. Jones, William Matsui, MD, Ivan M. Borrello, MD, Carol Ann Huff, M.D.

Blood (2013) 122 (21): 3407.

https://doi.org/10.1182/blood.V122.21.3407.3407

Published: 2013

NARROW

CD8 + T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Bone Marrow GZMK + IL7R + Progenitor-Exhausted CD8 + T Cells Correlate with Sustained Clinical Remission in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Treating MRD Positivity in Multiple Myeloma: An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Long-Term Remissions in Patients with Low Disease Burden

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Superior Efficacy of CAR-T Cells Using Marrow-Infiltrating Lymphocytes (MILs TM ) As Compared to Peripheral Blood Lymphocytes (PBLs)

Flowct: A Semi-Automated Workflow for Deconvolution of Immunophenotypic Data and Objective Reporting on Large Datasets

Marrow-Infiltrating Lymphocytes (MILs) Provide a Robust Platform for CAR-T Cell Therapy

FLT3 ITD AML Outcomes Are Impacted By Exposure to One Cycle of Cytarabine Based Consolidation, Pre- and Post-Transplant TKI Therapy, and Presence of Minimal Residual Disease (MRD) Prior to Allogeneic Blood or Marrow Transplant

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Impaired Response to Influenza Vaccination in AML Patients Post-Chemotherapy Associated with a Highly Atypical B-Cell Profile

Allogeneic Myeloma GVAX with Lenalidomide Enhances Progression Free Survival through the Generation of Tumor Specific Immunity in Patients in Near Complete Remission

The Long PD-1 Receptor Binding Kinetics of Nivolumab May Increase Efficacy of Subsequent Therapy in Relapsed and Refractory Multiple Myeloma Patients

Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only